And while we are on the subject of updates: Isnt about time this profile below on the ASX was corrected to reflect the true nature of the company.
"Cellmid Limited (CDY) is an Australian life sciences accelerator for indication of multiple diseases. It operates mainly through its wholly owned subsidiaries, Advangen Limited, Kinera and Lyramid Limited, that develop and market innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company holds global intellectual properties relating to novel targets midkine and FGF5."
Needs a bit of a sort out, as punters could be easily confused which has a tendency to send them elsewhere to the likes of lithium, gold, oil, copper, vanadium, graphite in search of the wholly Grey Owl. Some of them have huge numbers of shares traded in a day with multiple buyers and sellers.
No blame, no shame, just trying to be useful.
CDY Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held